| human | Q5 |
| P496 | ORCID iD | 0000-0002-2053-5315 |
| 0000-0002-9632-6691 | ||
| P1153 | Scopus author ID | 25638989800 |
| P69 | educated at | Pontifícia Universidade Católica do Paraná | Q1131088 |
| Universidade Federal do Paraná | Q1232831 | ||
| University of Campinas | Q2060678 | ||
| P734 | family name | Kotze | Q37486249 |
| Kotze | Q37486249 | ||
| Kotze | Q37486249 | ||
| P735 | given name | Paulo | Q18385147 |
| Paulo | Q18385147 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q34429934 | (N-Benzoyl-N'-phenyl-thio-urea-κS)chlorido(η-1,5-cyclo-octa-diene)rhodium(I) |
| Q60588830 | A broad panel of autoantibodies in patients with celiac disease and Crohn's disease |
| Q47700572 | ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY. |
| Q51701731 | ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL. |
| Q47754100 | Adalimumab and postoperative complications of elective intestinal resections in Crohn's disease: a propensity score case-matched study. |
| Q43515258 | Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study. |
| Q87665967 | Adalimumab for perianal fistulizing Crohn's disease: real-world data adds important information for clinical practice |
| Q47746921 | Adductor canal block--or subsartorial canal block? |
| Q86121778 | Anal Fistula Plug for Perianal Fistulising Crohn's Disease: an Important Trial for Inflammatory Bowel Disease Surgeons |
| Q42408142 | Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy |
| Q95431730 | Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery |
| Q60588834 | Antibodies anti-Saccharomyces cerevisiae (ASCA) do not differentiate Crohn's disease from celiac disease |
| Q90844831 | BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES |
| Q98164815 | Biologics and surgical outcomes in Crohn's disease: is there a direct relationship? |
| Q92590726 | Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap? |
| Q40897367 | Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists. |
| Q48086247 | Burrill Bernard Crohn (1884-1983): the man behind the disease. |
| Q89486595 | Can Surgery for Inflammatory Bowel Disease be Personalized? |
| Q92046642 | Cell-based Therapy for Perianal Fistulising Crohn's Disease |
| Q33819500 | Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease. |
| Q49218809 | Clinical utility of ustekinumab in Crohn's disease. |
| Q49427029 | Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease. |
| Q60588824 | Complications after intestinal resection in Crohn's disease: laparoscopic versus conventional approach |
| Q90354695 | Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab |
| Q42104083 | Conventional Versus Biological Therapy for Prevention of Postoperative Endoscopic Recurrence in Patients With Crohn's Disease: an International, Multicenter, and Observational Study |
| Q92001440 | Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease |
| Q51118505 | Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet. |
| Q53629435 | Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. |
| Q69872635 | Diaphragm pacing in the treatment of ventilatory failure |
| Q41144584 | Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database |
| Q41345068 | Disease duration did not influence the rates of loss of efficacy of the anti-TNF therapy in Latin American Crohn’s disease patients. |
| Q91100735 | ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications |
| Q91100748 | ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects |
| Q38845478 | Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. |
| Q91195698 | Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? |
| Q51406075 | Effect of anti-TNF-α on peritoneal endometrial implants of rats. |
| Q92081099 | Effects of anti-TNF-α in experimental diversion colitis |
| Q41873906 | Endoscopic postoperative recurrence rates in Crohn's disease in Korea: the beginning of a new approach? |
| Q60588826 | Epidemiological profile of 175 patients with Crohn's disease submitted to biological therapy |
| Q38258954 | European evidence based consensus on surgery for ulcerative colitis |
| Q51021353 | FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. |
| Q39108648 | Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn's disease: a multicentre observational study |
| Q89589393 | Fistula-associated anal carcinoma in Crohn's disease |
| Q49787514 | Fluorescence angiography during transanal trans-stomal proctectomy and ileal pouch anal anastomosis: a video vignette. |
| Q47992176 | Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn's Disease and Individuals with Obesity Before and After Bariatric Surgery |
| Q38912005 | Heteroditopic P,N ligands in gold(I) complexes: synthesis, structure and cytotoxicity. |
| Q61809273 | Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatients |
| Q104490378 | INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE |
| Q92379052 | Ileal pouch-anal anastomosis with fluorescence angiography: a case-matched study |
| Q92341739 | Impact of Preoperative Nutritional Status on the Incidence Rate of Surgical Complications in Patients With Inflammatory Bowel Disease With Vs Without Preoperative Biologic Therapy: A Case-Control Study |
| Q45810000 | Infliximab versus azathioprine to prevent postoperative recurrence in Crohn's disease: are all controversial issues defined? |
| Q45291581 | Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn's disease? |
| Q36105770 | Islet cell research brings hope for a diabetes cure: meeting report from the 6(th) annual islet society meeting in Stellenbosch, South Africa |
| Q57455138 | Letter: can a specific surgical approach reduce post-operative recurrence in Crohn's disease? |
| Q92076372 | Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? |
| Q90578318 | Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents? |
| Q95337660 | Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice |
| Q54987397 | Long Time from Diagnosis to Surgery May Increase Postoperative Complication Rates in Elective CD Intestinal Resections: An Observational Study. |
| Q90299443 | Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases |
| Q92150597 | Mesenchymal Stem Cells for Perianal Crohn's Disease |
| Q47733479 | Modern management of perianal fistulas in Crohn's disease: future directions. |
| Q84523297 | Motor neuropathy with multiple conduction blocks associated with TNF-alpha antagonist |
| Q53154433 | Obesity and Crohn's disease: what comes first, the egg or the chicken? |
| Q98906899 | Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? |
| Q38621576 | POSTOPERATIVE APPROACH FOR CROHN'S DISEASE: THE RIGHT THERAPY TO THE RIGHT PATIENT. |
| Q114668091 | Perception and clinical decisions from inflammatory bowel diseases’ specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB) |
| Q51017516 | Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn's disease: a Brazilian multicenter observational study. |
| Q47858782 | Postoperative topical analgesia of hemorrhoidectomy with policresulen and cinchocaine: a prospective and controlled study |
| Q46740842 | Pre hospital administration of prothrombin complex concentrate in the head injured patient, a service evaluation. |
| Q92194584 | Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)? |
| Q47689139 | Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire? |
| Q39316824 | Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls |
| Q92508835 | Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile |
| Q90659209 | Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease |
| Q38455953 | Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease--Focus on clinical evaluation of m |
| Q90961612 | Redo pouch and re-stapled anastomosis after intra-operative detection of pouch ischaemia by fluorescence angiography - a video vignette |
| Q92807380 | Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis |
| Q94915014 | Reduction of surgical rates in inflammatory bowel diseases biologic era: similarities between Spain and Latin America |
| Q47688791 | Reply to Dr Bendtsen. |
| Q102148322 | Research in inflammatory bowel disease in Brazil: a step forward towards patient care |
| Q44675776 | Research in inflammatory bowel diseases in Latin America: a challenge ahead. |
| Q38716515 | Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs. |
| Q97644842 | Review of the epidemiology and burden of ulcerative colitis in Latin America |
| Q37744596 | Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study |
| Q60588817 | Risk factors for postoperative endoscopic recurrence in Crohn's disease: a Brazilian observational study |
| Q47736120 | SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB. |
| Q90461513 | SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT |
| Q90432516 | Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies? |
| Q40288106 | Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). |
| Q50055388 | Staging surgery for ulcerative colitis: more than meets the eye. |
| Q90642834 | Surgery in ulcerative colitis: When? How? |
| Q87365165 | T300A genetic polymorphism: a susceptibility factor for Crohn's disease? |
| Q51713787 | THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era. |
| Q90461519 | TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES |
| Q93022281 | The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil |
| Q90642837 | The impact of biologics in surgical outcomes in ulcerative colitis |
| Q87056174 | The impact of preoperative anti-TNF in surgical and infectious complications of abdominal procedures for Crohn's disease: controversy still persists |
| Q92116046 | The impact of surgical therapies for inflammatory bowel disease on female fertility |
| Q55175032 | The old versus the new: which do you keep in postoperative Crohn's disease? |
| Q51957011 | Three model curricula for teaching clinicians to use the ICF. |
| Q91592897 | Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development |
| Q40416993 | Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease |
| Q90844821 | VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY |
| Q90461451 | VISCERAL FAT IS INCREASED IN INDIVIDUALS WITH CROHN'S DISEASE: A COMPARATIVE ANALYSIS WITH HEALTHY CONTROLS |
| Q55438978 | Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. |
Search more.